Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02 Billion in 2022 and is predicted to reach 26.14 Billion by the year 2031 at a 20.5 % CAGR during the forecast period for 2023-2031.
Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/1218
Biosimilars are biological therapeutics. In terms of quality, efficacy, and safety, they are equivalent to an innovative reference medicinal product. Biosimilar Monoclonal Antibodies are complex biological macromolecules that have undergone numerous post-translational modifications. These biosimilars are widely employed in the treatment of numerous chronic, inflammatory, and autoimmune conditions. The Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMEA) in Europe regulate biosimilars.
Increasing demand for cost-effective biosimilars, rising production of advanced monoclonal antibodies, a growing geriatric population, and the prevalence of chronic diseases such as cancer, kidney failure, rheumatoid arthritis, psoriasis, and diabetes all contribute to the growth of the global biosimilar monoclonal antibodies market. In addition, the growing number of Monoclonal Antibodies (mAbs) whose patents are set to expire in the coming years is anticipated to boost the market's growth prospects over the forecast period. Increased patent expirations of effective antibodies have prompted pharmaceutical companies to develop biosimilars for mAbs, which is expected to boost the market during the forecast period.
Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1218
However, the growth of the market is anticipated to be hampered by the complexities of manufacturing biological drugs, the dearth of clinical trial expertise, strict government policies for product approvals, and the lack of understanding among manufacturers regarding biosimilars regulation and approval.
Major market players operating in the biosimilar monoclonal antibodies market include Pfizer (US), Novartis (Switzerland), Allergan (Ireland), Coherus BioSciences (US), Biocon (Bengaluru), Amgen (US), Boehringer Ingelheim (Germany), Celltrion (South Korea), BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia) among others.
Key developments in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support biosimilar development for third-party customers. This partnership created an integrated solution between two leading service providers in biosimilar development and GMP manufacture.
• In February 2020, Mylan (US) launched its trastuzumab biosimilar, Ogivri. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-receptor-positive breast cancer, previously marketed by Genentech as Herceptin.
• In June 2019, Amgen (US) and Allergan (Ireland) announced the FDA approval for KANJINTI™ (trastuzumab-anns). It is approved for all indications of the reference product, Herceptin® (trastuzumab), providing an additional treatment option for patients across three types of cancer.
Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1218
Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2020-2030 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Indication, 2020-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should get this report:
> To receive a thorough clinical trial/pipeline analysis of the prospects for the global biosimilar monoclonal antibodies market
> To get an market overview and future trends of the biosimilar monoclonal antibodies industry
> To analyze the biosimilar monoclonal antibodies market drivers and challenges
> To get information on the biosimilar monoclonal antibodies market size (Value US$ Mn) forecast to 2030
> Major investments, mergers & acquisitions in the biosimilar monoclonal antibodies market industry
For More Information: https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218
Other Related Reports Published by InsightAce Analytic:
Global Trastuzumab Biosimilar Market
Global Adalimumab Biosimilar Market
Global Infliximab Biosimilar Market
Global Bevacizumab Biosimilar Market
Corporate Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
loaction icon
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
email iconinfo@insightaceanalytic.com
call icon
North America:
+1 551 226 6109
Asia:
+91 79 72967118
Contact Us:
Dhanraj Zurange
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Market here
News-ID: 3382201 • Views: …
More Releases from Insightace analytic
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031"
The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%…
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031
"Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by…
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals…
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031"
The Global Data Center Liquid Cooling Market is estimated…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…